November 21, 2013Open Access

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

JDJ.-Y. Douillard GOGyula OstorosOrszágos Korányi Tbc és Pulmonológiai Intézet MCManuel CoboHospital Regional Universitario de Málaga

Key Points

Key points are not available for this paper at this time.

Abstract

First-line gefitinib was effective and well tolerated in Caucasian patients with EGFR mutation-positive NSCLC. Plasma samples could be considered for mutation analysis if tumour tissue is unavailable.

KI fragen

Bookmark

View Full Paper